Table 1 Patient, tumour, and treatment characteristics for the training and validation data.
Variable | Training data (122) | Validation data (68) | p-value | ||
|---|---|---|---|---|---|
Median | Range | Median | Range | ||
Age (years) | 59.5 | 24–79 | 63.5 | 21–86 | 0.26 |
Number | % | Number | % | ||
Gender | |||||
Male/female | 79/43 | 65/35 | 48/20 | 71/29 | 0.51 |
cT | |||||
2/3/4/unknown | 6/98/18/0 | 5/80/15/0 | 7/53/7/1 | 10/78/10/2 | 0.23 |
cN | |||||
0/1/2/3/unknown | 7/112/2/1/0 | 6/92/2/1/0 | 8/54/1/4/1 | 11/79/2/6/2 | 0.06 |
Grading | |||||
0/1/2/3/unknown | 10/5/71/36/0 | 8/4/58/30/0 | 4/3/53/5/3 | 6/4/78/8/4 | 0.001 |
UICC stage | |||||
1/2/3/4/unknown | 0/7/115/0/0 | 0/6/94/0/0 | 1/7/52/3/5 | 2/10/77/4/7 | < 0.001 |
Localization (cm) | |||||
3–6/> 6–12/> 12–16 | 65/54/3/0 | 53/44/3/0 | 24/37/6/1 | 35/54/9/2 | 0.02 |
RT dose (Gy) | |||||
50.4/45 | 95/27 | 78/22 | 66/2 | 97/3 | < 0.001 |
Chemotherapy regimen | |||||
5FU/5FU + OX/CAP/CAP + other | 97/10/7/8 | 80/8/6/7 | 59/7/2/0 | 87/10/3/0 | 0.13 |
Response (TRG) | |||||
0/1/2/3/4 | 0/23/61/24/14 | 0/19/50/20/11 | 3/14/30/10/11 | 4/21/44/15/16 | 0.13 |
Distant metastases | |||||
No/yes | 103/19 | 84/16 | 52/16 | 76/24 | 0.25 |
